Principal Financial Group Inc. Buys 8,980 Shares of Bruker Corporation $BRKR

Principal Financial Group Inc. boosted its stake in Bruker Corporation (NASDAQ:BRKR) by 3.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 247,383 shares of the medical research company’s stock after purchasing an additional 8,980 shares during the quarter. Principal Financial Group Inc. owned about 0.16% of Bruker worth $8,935,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Royal Bank of Canada increased its holdings in shares of Bruker by 8.3% in the 1st quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company’s stock worth $5,148,000 after buying an additional 9,501 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in shares of Bruker during the 1st quarter worth $262,000. Goldman Sachs Group Inc. lifted its holdings in shares of Bruker by 107.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock worth $61,162,000 after acquiring an additional 758,301 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Bruker by 2.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company’s stock worth $15,285,000 after acquiring an additional 9,235 shares in the last quarter. Finally, Focus Partners Wealth grew its position in Bruker by 115.0% in the first quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company’s stock worth $469,000 after acquiring an additional 6,008 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors.

Bruker Stock Performance

Bruker stock opened at $60.45 on Monday. The firm has a fifty day simple moving average of $56.32 and a two-hundred day simple moving average of $46.29. The company has a quick ratio of 0.72, a current ratio of 1.55 and a debt-to-equity ratio of 0.67. Bruker Corporation has a twelve month low of $28.53 and a twelve month high of $64.54. The company has a market capitalization of $9.20 billion, a PE ratio of -251.88, a P/E/G ratio of 1.94 and a beta of 1.29.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. The firm had revenue of $823.40 million for the quarter, compared to analysts’ expectations of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The company’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period last year, the firm earned $0.47 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Research analysts expect that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 22nd were given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date was Monday, June 22nd. Bruker’s dividend payout ratio (DPR) is presently -83.33%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on BRKR shares. Citigroup raised their price target on Bruker from $44.00 to $60.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. JPMorgan Chase & Co. increased their price objective on Bruker from $55.00 to $65.00 and gave the company an “overweight” rating in a research report on Monday, June 8th. TD Cowen reissued a “hold” rating on shares of Bruker in a report on Wednesday, July 15th. Guggenheim raised their price objective on Bruker from $50.00 to $70.00 and gave the company a “buy” rating in a report on Monday, June 29th. Finally, Wall Street Zen upgraded Bruker from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $56.79.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.